166 related articles for article (PubMed ID: 26641143)
1. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?
Dongiovanni P; Rametta R; Meroni M; Valenti L
Expert Rev Gastroenterol Hepatol; 2016; 10(2):229-42. PubMed ID: 26641143
[TBL] [Abstract][Full Text] [Related]
2. Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD.
Vacca M; Allison M; Griffin JL; Vidal-Puig A
Semin Liver Dis; 2015 Aug; 35(3):250-61. PubMed ID: 26378642
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
Gastaldelli A
Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
[TBL] [Abstract][Full Text] [Related]
4. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
Sun X; Zhang Y; Xie M
Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
[TBL] [Abstract][Full Text] [Related]
5. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
[TBL] [Abstract][Full Text] [Related]
6. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.
Ercin CN; Dogru T; Genc H; Celebi G; Aslan F; Gurel H; Kara M; Sertoglu E; Tapan S; Bagci S; Rizzo M; Sonmez A
Metab Syndr Relat Disord; 2015 Sep; 13(7):319-25. PubMed ID: 26011302
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies.
Zhang CH; Zhou BG; Sheng JQ; Chen Y; Cao YQ; Chen C
Pharmacol Res; 2020 Sep; 159():104984. PubMed ID: 32502637
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
9. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
Wree A; Mehal WZ; Feldstein AE
Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
[TBL] [Abstract][Full Text] [Related]
10. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease.
Azzu V; Vacca M; Virtue S; Allison M; Vidal-Puig A
Gastroenterology; 2020 May; 158(7):1899-1912. PubMed ID: 32061598
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
12. Elovl6 promotes nonalcoholic steatohepatitis.
Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H
Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
Başaranoğlu M; Örmeci N
Turk J Gastroenterol; 2014 Apr; 25(2):127-32. PubMed ID: 25003670
[TBL] [Abstract][Full Text] [Related]
17. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
[TBL] [Abstract][Full Text] [Related]
18. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
Elshazly SM
Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.
Roden M
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
